
1. malar j. 2013 dec 19;12:454. doi: 10.1186/1475-2875-12-454.

immunogenicity bacterial-expressed recombinant plasmodium knowlesi merozoite
surface protein-142 (msp-142).

cheong fw, fong my(1), lau yl, mahmud r.

author information: 
(1)department parasitology, faculty medicine, university malaya, 50603, 
kuala lumpur, malaysia. fongmy@um.edu.my.

background: plasmodium knowlesi fifth plasmodium species infect
humans. plasmodium merozoite surface protein-1(42) (msp-1(42)) potential
candidate malaria vaccine. however, limited studies focused p.
knowlesi msp-1(42).
methods: ~42 kda recombinant p. knowlesi msp-1(42) (pkmsp-1(42)) expressed 
using escherichia coli system. purified pkmsp-1(42) evaluated with
malaria non-malaria human patient sera (n = 189) using western blots and
elisa. immunogenicity pkmsp-1(42) evaluated mouse model.
results: purified pkmsp-1(42) sensitivity 91.0% detection of
human malaria assays. specificity 97.5 92.6% western blots and
elisa, respectively. levels cytokine interferon-gamma, interleukin-2,
interleukin-4, interleukin-10 significantly increased in
pkmsp-1(42)-immunized mice compared negative control mice.
pkmsp-1(42)-raised antibody high endpoint titres, igg isotype
distribution igg1 > igg2b > igg3 > igg2a.
conclusions: pkmsp-1(42) highly immunogenic able detect human malaria.
hence, pkmsp-1(42) would useful candidate malaria vaccine development
and seroprevalence studies.

doi: 10.1186/1475-2875-12-454 
pmcid: pmc3878241
pmid: 24354660  [indexed medline]

